TABLE 1.
Clinical characteristics of ovarian cancer cases in NHS, NHSII, and NECC studies by aspirin use status. a
| Low‐dose aspirin use | Regular‐dose aspirin use | |||
|---|---|---|---|---|
| Current | Never | Current | Never | |
| (n = 33) | (n = 59) | (n = 61) | (n = 92) | |
| Calendar year at diagnosis, median (Q1‐Q3) | 2007 (2005–2009) | 2005 (2002–2008) | 2003 (1999–2007) | 2004 (2001–2007) |
| Age at diagnosis, years, median (Q1‐Q3) | 73 (62–78) | 63 (55–71) | 68 (61–75) | 57 (50–63) |
| Study, n (%) | ||||
| NECC | 0 (0%) | 0 (0%) | 4 (7%) | 68 (74%) |
| NHS | 26 (79%) | 35 (59%) | 50 (82%) | 4 (4%) |
| NHSII | 7 (21%) | 24 (41%) | 7 (11%) | 20 (22%) |
| Stage, n (%) | ||||
| I | 4 (12%) | 12 (20%) | 9 (15%) | 12 (13%) |
| II | 3 (9%) | 4 (7%) | 6 (10%) | 10 (11%) |
| III | 22 (67%) | 36 (61%) | 38 (62%) | 62 (67%) |
| IV | 4 (12%) | 6 (10%) | 8 (13%) | 6 (7%) |
| Missing | 0 (0%) | 1 (2%) | 0 (0%) | 2 (2%) |
| Histology | ||||
| High‐grade serous/poorly differentiated | 31 (94%) | 48 (81%) | 54 (89%) | 88 (97%) |
| High grade endometrioid | 2 (6%) | 11 (19%) | 7 (11%) | 3 (3%) |
Abbreviations: NHS, Nurses' Health Study; NHSII, Nurses' Health Study II; NECC, New England Case–Control Study; Q, quartile.
a
Current use was defined as having used low‐dose aspirin or regular‐dose aspirin 1–2 years prior to ovarian cancer diagnosis, never use was defined as having never regularly used low‐dose aspirin or regular‐dose aspirin prior to ovarian cancer diagnosis.